A suit of armor for cancer-fighting cells
A suit of armor for cancer-fighting cells In recent years, cancer researchers have hailed the arrival of chimeric antigen receptor T cell (CAR T) therapy, which has delivered promising results, transforming the fight against various forms of cancer. The process…
Biocytogen officially launches the RenMice
Biocytogen officially launches the RenMice Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) officially announces the RenMice ® series , which includes a collection of independently developed fully human antibody mice and TCR mice with proprietary intellectual property. The term “Ren”, defined as “human”,…
Emulate Publishes Novel Framework to Pave the Way for the Integration of Liver-Chip Technology into Pharmaceutical Safety Assessment
Emulate Publishes Novel Framework to Pave the Way for the Integration of Liver-Chip Technology into Pharmaceutical Safety Assessment Emulate, Inc., the leading provider of next-generation in vitro models, today announced the publication “Integrating Liver-Chip Data into Pharmaceutical Decision-Making Processes” in Expert Opinion…
Quizartinib Recommended for Approval in EU by CHMP for Patients with Newly Diagnosed FLT3-ITD Positive AML
Quizartinib Recommended for Approval in EU by CHMP for Patients with Newly Diagnosed FLT3-ITD Positive AML Daiichi Sankyo announced that quizartinib has been recommended for approval in the European Union (EU) in combination with standard cytarabine and anthracycline induction and standard…
Merck Receives Positive EU CHMP Opinion for KEYTRUDA as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy Merck (NYSE: MRK), known as MSD outside of the United States…
Therapeutic Solutions International Subsidiary Discloses Potential Solution to Immunotherapy Resistance in Cancer by “Healing Tumor” Before Killing It
Therapeutic Solutions International Subsidiary Discloses Potential Solution to Immunotherapy Resistance in Cancer by “Healing Tumor” Before Killing It The conventional dogma, which is supported by numerous well performed studies, is that stem cell administration helps cancer to grow. This is…
EBGLYSS Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis
EBGLYSS® (lebrikizumab) Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis The positive CHMP opinion is now being reviewed by the European Commission (EC). The approval of this biologic in the European Union is expected in approximately two months and its launch…
Global Cell Freezing Media Market to Reach $291.3 Million by 2030 – Driven by Rising Adoption of Ready-to-Use Freezing Media – ResearchAndMarkets.com
Global Cell Freezing Media Market to Reach $291.3 Million by 2030 – Driven by Rising Adoption of Ready-to-Use Freezing Media – ResearchAndMarkets.com The “Cell Freezing Media Market Size, Share & Trends Analysis Report By Product (DMSO, Glycerol), By Application (Stem Cell…
AGC Biologics Offers Guaranteed Delivery of at least 1e11 TU of LVV Material in Nine Months
AGC Biologics Offers Guaranteed Delivery of at least 1e11 TU of LVV Material in Nine Months –AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a Lentiviral vector (LVV) expansion to its AGCellerate program designed to deliver…
Biomedicines Announces Close of $273M Series C Financing to Advance Its Generative AI Pipeline of Preclinical and Clinical Protein Therapeutics
Biomedicines Announces Close of $273M Series C Financing to Advance Its Generative AI Pipeline of Preclinical and Clinical Protein Therapeutics Biomedicines, a clinical-stage biotherapeutics company pioneering a machine-learning-powered generative biology platform, today announced that it has raised $273 million in…
Boehringer Ingelheim receives SBTi validation for CO2 reduction targets
Boehringer Ingelheim receives SBTi validation for CO2 reduction targets Boehringer Ingelheim, a leading research-driven biopharmaceutical company, said on Thursday it is well on track to achieve its 2030 emission reduction targets, and that it had received approval of those targets…
AstraZeneca advances UK clean heat and energy efficiencies with £100m commitment
AstraZeneca advances UK clean heat and energy efficiencies with £100m commitment Powering AstraZeneca’s transition to net zero, the Company has agreed a 15-year partnership with Future Biogas to establish the UK’s first unsubsidised industrial-scale supply of biomethane gas, and is…